ACE and heart failure: Finally, the PARADIGM (Prospective Comparison of angiotensin receptor-neprilysin inhibitor (ARNI) with an angiotensin-converting enzyme (ACE) inhibitor to Determine Impact on Global Mortality and Morbidity in Heart Failure) study findings show that, although the benefit of sacubitril/valsartan over enalapril was still evident in patients with SBP < 120 mmHg, it was significantly more decreased than those with SBP ≥120 mmHg [66].